a maintenance pill to be used after concluding the main weight loss phase with an injectable
The decision to prescribe these medications should weigh the substantial metabolic benefits against individual gallbladder risk, recognizing that for most patients, the cardiovascular and glycemic advantages outweigh the relatively modest absolute risk increase
Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial
If you notice emotional dips or obsessive thoughts, speak up early
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations Cancer Network Staff Tim Cortese , Russ Conroy Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease
Chiu and your anesthesia team if you have: Nausea or vomiting Constipation or bloating Abdominal pain or reflux A recent dose increase A newly started GLP-1 medication Poor appetite or low protein intake Rapid weight loss Diabetes or blood sugar changes A history of gastroparesis or slow digestion These details help your team decide whether to move forward, need a modified plan, or wait until symptoms improve
